Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 891,857 |
|
|||||
| News | - | ||||||
| Day High | 15.65 | Low High |
|||||
| Day Low | 14.64 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immunome Inc | IMNM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.30 | -1.96% | 14.98 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 15.32 | 14.64 | 15.65 | 14.66 | 15.28 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,433 | 891,857 | $ 15.29 | $ 13,639,159 | - | 4.44 - 30.958 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:23:02 | 2 | $ 14.81 | USD |
Immunome Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 625.56M | 42.73M | - | 14.02M | -106.81M | -2.50 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Immunome News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMNM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 18.46 | 19.0699 | 14.64 | 16.39 | 1,217,202 | -3.48 | -18.85% |
| 1 Month | 24.00 | 26.70 | 14.64 | 19.72 | 811,400 | -9.02 | -37.58% |
| 3 Months | 19.40 | 30.958 | 14.64 | 22.18 | 799,131 | -4.42 | -22.78% |
| 6 Months | 8.82 | 30.958 | 6.93 | 19.28 | 510,817 | 6.16 | 69.84% |
| 1 Year | 5.31 | 30.958 | 4.44 | 16.66 | 330,652 | 9.67 | 182.11% |
| 3 Years | 31.01 | 32.4476 | 2.09 | 15.85 | 188,689 | -16.03 | -51.69% |
| 5 Years | 15.66 | 63.78 | 2.09 | 17.78 | 184,117 | -0.68 | -4.34% |
Immunome Description
| Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. |
